Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · IEX Real-Time Price · USD
-0.25 (-1.36%)
Jul 19, 2024, 2:16 PM EDT - Market open

Company Description

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.

Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.

In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.

It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT.

The company was incorporated in 2013 and is headquartered in Shanghai, China.

Zai Lab Limited
Zai Lab logo
Country China
Founded 2013
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 2,175
CEO Dr. Ying Du Ph.D.

Contact Details

4560 Jinke Road, Bldg. 1, 4f, Pudong
Shanghai, F4 201210
Phone 862161632588

Stock Details

Ticker Symbol ZLAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001704292
CUSIP Number 98887Q104
ISIN Number US98887Q1040
SIC Code 2834

Key Executives

Name Position
Dr. Ying Du Ph.D. Founder, Chairperson and Chief Executive Officer
Joshua L. Smiley President and Chief Operating Officer
Dr. Rafael G. Amado M.D. President and Head of Global Oncology Research and Development
Dr. Harald Reinhart M.D. President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Dr. Yajing Chen Ph.D. Chief Financial Officer
Dr. Peter Huang Ph.D. Chief Scientific Officer
Christine Chiou Senior Vice President and Head of Investor Relations
Frazor Titus Edmondson III, J.D. Chief Legal Officer and Corporate Secretary
Ann E. Beasley J.D. Chief Compliance Officer
Dr. Ning Xu M.D. Executive Vice President and Head of Clinical Operations

Latest SEC Filings

Date Type Title
Jul 9, 2024 8-K Current Report
Jul 1, 2024 144 Filing
Jul 1, 2024 144 Filing
Jul 1, 2024 144 Filing
Jun 26, 2024 144 Filing
Jun 26, 2024 144 Filing
Jun 26, 2024 144 Filing
Jun 26, 2024 144 Filing
Jun 18, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 18, 2024 8-K Current Report